Podcast Episode 3: The Pathologist-Oncologist Connection: Optimal Reporting of the PD-L1 Results

In this third episode of the "Dialogues in CDx" podcast series, you’ll listen to the distinguished guests Dr. Phillippe Taniere and Dr. Shobhit Baijal once more. The previous episode dissected the PD-L1 testing journey from biopsy to report. This episode will focus on the topic of PD-L1 reporting: What information should the pathologist provide for the oncologist? What information helps the oncologist make the best treatment decisions?

As in the second episode, perspectives from both a pathologist and an oncologist are presented. Dr. Phillipe Tanière is a Consultant Histopathologist and Clinical Service Lead for Molecular Pathology at University Hospitals Birmingham in UK. Dr. Tanière’s department completed 20,000 CDx tests last year.

Also joining the discussion is Dr. Shobhit Baijal, a Consultant Medical Oncologist at the University Hospitals Birmingham NHS Trust and an Honorary Associate Professor at the University of Birmingham, where he specializes in the treatment of thoracic and colorectal malignancies. Dr. Baijal specializes in all forms of cancer therapy and is a UK Chief and Principal Investigator for National and International studies. He is also a steering committee member of the British Thoracic Oncology Group. His vast experience provides invaluable input to the discussion.

The topics covered in this conversation include:

•  The role of concordance studies for PD-L1 testing
•  The oncologist’s interest in the assay used
• Information the pathologist should provide for the oncologist
• Whether the oncologist needs a percentage figure or an exact score
• Whether the oncologist wants treatment recommendations or not

The views and opinions expressed by the guests on this podcast are their own and do not necessarily reflect the views or opinions of the host or of Agilent.

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.D0131924_1.00